Prof. Jeff Jianfei Guo

University of Cincinnati, USA

Email: jeff.guo@uc.edu

Qualifications

2000 Professor, University of Cincinnati Medical Center, Pharmacoepidemiology and Pharmacoeconomics
1983 Drug Information/Clinical Informatics Specialist, The United States Pharmacopeia

Publications (Selected)

1. Guo JJ, Tsai K, Kelton CML, Bian B, Wigle PR. Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma. Ann Allergy Asthma Immuno 2010;106(3): 214-222.e2. Epub 2011 Jan 17.
2. Zhang YJ, Liu WW, Wang JB, Guo JJ. Potentially inappropriate medication use among elderly population in the US population. Age and Aging. 2011; 10: doi:10.1093/ageing/afr012.
3. Yan WC, Zhang YJ, Guo JJ. Still some way to go in China: international tobacco control. [commentary] British Medical Journal BMJ 2010; 341: c6659.
4. Bian BB, Guo JJ*, Kelton CML, Wigle PR. Utilization and expenditure trends of ACE inhibitors and ARBs in the Medicaid program. J Managed Care Pharmacy. 2010; 16(9): 671-679.
5. Wade TJ, Guo JJ. Cost-effectiveness analysis for the school-based health centers program. J Am Pub Health Assoc. Feb 2010; 100(5): 1611-1616.
6. Guo JJ, Wade TJ, Pan W, Keller KN. School-Based Health Centers: cost-benefit analysis and healthcare disparity. J Am Pub Health Assoc. Feb 2010; 100(5): 1617-1623.
7. Guo JJ, Pandey S, Doyle J, Bian B, Raisch D. A review of current risk-benefit assessments for drug safety: report of ISPOR risk-benefit management working group. Value in Health. May 2010; 13(5): 657-666.
8. Vaidya S, Guo JJ*, Heaton PC, Steinbuch M. Comparison of post-marketing drug safety surveillance in some developing countries. Drug Information Journal. 2010; 44: 519-533.
9. Guo JJ, Patel N, Li H, Keck PE. Prevalence for Treated Bipolar Spectrum Disorder and Associated Comorbidities in Medicaid and Managed Care Populations. Am Health Drug Benefit 2010; 3(3): 171-178.
10. Bian B, Guo JJ**. The FDA Amendment Act and its impact on pharmaceutical industry. Chinese J Pharmacovigilance 2010; 7(4): 221-223.
11. Zhang YJ, Guo JJ, Wang JB.  The Orphan Drug Act and its impact on new drug development. Chinese J Pharmaceutical Economics Policy. 2010; 22(1): 27-33.
12. Bian B, Kelton CML, Guo JJ*, Wigle PR. Evaluating safety of long-acting beta agonists (LABAs) in patients with asthma. Current Drug Safety. March 2010; 5 (3): 245-250.
13. Roddy J, Partridge S, Rockey M, Pruemer J, Guo JJ, Desai S, Safa M. Thromboembolic Events in Patients with Colorectal Cancer Receiving the Combination of Bevacizumab-based Chemotherapy and Erythropoietin Stimulating agents. Am J Clinical Oncology 2010; 33(1): 36-42.
14. Wang JB, Guo JJ, Yang L, Zhang YD, Sun ZQ, Zhang YJ. Rare diseases and legislation in China. The Lancet 2010; 375: 708-709.
15. Chen Y, Guo JJ, Steinbuck M, Buckley PF, Patel C. Risk of neuroleptic malignant syndrome associated with the use of antipsychotics in patients with bipolar disorder: a retrospective, population-based case-control study. International J Psychiatry Med. 2009; 39(4): 439-450.
16. Demland J, Jing Y, Kelton CML, Guo JJ, Li H, Wiggle PR. Drug utilization pattern and off-label use of atypical antipsychotics in patients with bipolar disorder:1998-2002. Am Health Drug Benefit 2009; 2(4): 184-191.
17. Chen Y, Guo JJ, Patel NC. Hemorrhagic stroke associated with antidepressant use in patients with depression: does degree of serotonin reuptake inhibition matter? Pharmacoepidemiol Drug Saf2009; 18(3):196-202. (the best research paper award of the year 2009)
18. Guo JJ, Kelton CML. The role of epidemiology for drug development. Am Health Drug Benefit. 2009; 2(1 supplement): S49-54.
19. Chen Y, Guo JJ, Healy D, Lin X, Patel NC. Risk of Hepatotoxicity Associated with the Use of Telithromycin: Signal Detection Based upon the FDA’s Spontaneous Reporting System. Annals Pharmacotherapy. Dec 2008; 42(12): 1791-6.
20. Chen Y, Guo JJ, Steinbuck M, Lin XD, Buncher CR. Patel C. Comparisons of Data Mining Algorithms for Adverse Drug Reactions: An Empirical Study based on the Adverse Event Reporting System of the Food and Drug Administration. J Pharm Med 2008; 22(6): 359-65.
21. Guo JJ, Jing Y, Nguyen K, Fan H, Li X, Kelton CM. Principal components analysis of drug utilization and expenditure trends for major therapeutic classes in U.S. Medicaid programs. Journal of Medical Economics. 2008; 11: 671-694.
22. Guo JJ, Goehring E, Jones JK. The Story of cisapride and Its Withdraw from Market: A Case Study. [Book Chapter 29] In: Hartzema AG, Tilson HH, Chan AK, eds. Pharmacoepidemiology and Therapeutic Risk Management. Harvey Whitney Books. Cincinnati, Ohio. 2008. pp.727-738.
23. Guo JJ, Kelton C. Patent protected brand-name drugs and competition between brand-name and generic drugs. [Chapter 20] In: Fulda T, Wertheimer A, eds. Handbook of Pharmaceutical Public Policy. ISBN:978-0-7890-3058-0. Haworth Press Inc. New York. 2007. pp. 395-416.
24. Wade TJ, Keller KN, Guo JJ, Huentelman T, Line K, Mansour ME. Access and utilization patterns across the first three years of implementation of elementary and middle school school-based health centers. Public Health Reports 2008; 123(6): 739-750.